- Kuria's Chief Operating Officer, Dr. Misty Stevens, to present company overview and host face-to-face booth presentation
Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, is pleased to announce that its co-founder and COO, Dr. Misty Stevens, will be presenting at the InvestMidwest meeting, April 17-18 2024, in Kansas City, MO.
The InvestMidwest forum emphasizes the strengths of the Midwest innovation ecosystem including healthcare and life sciences. Kuria is one of 41 companies selected through a competitive application process for a platform presentation at the meeting.
Dr. Stevens will present recent updates on Kuria's development programs and further introduce the company to the venture community, and will be available for one-on-one meetings during the event.
About Kuria Therapeutics, Inc.:
Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.
Contacts
Investor Relations and Media Kuria Therapeutics: Corporate Communication info@kuriatx.com